Skyway Capital Markets Advises SPAC on USD 85m Medical Technology Merger.

MANews-(C)2009-2022

US-based boutique investment bank Skyway Capital Markets, LLC advised special purpose acquisition company LMF Acquisition Opportunities, Inc. (NASDAQ: LMAO) in its merger with US-based medical technology company SeaStar Medical, Inc, the firm said.

Skyway Capital Markets LLC served as sole financial and valuation advisor to LMAO in connection with the proposed business combination.

The transaction is expected to provide SeaStar Medical with access to the capital markets and thereby position the company to accelerate the development and advancement of its lead programs for acute kidney injury in both pediatric and adult patients, as well as advance other SeaStar Medical programs in acute and chronic indications.

SeaStar Medical's Selective Cytopheretic Device is a patented, cell-directed, extracorporeal immunomodulator that selectively targets activated neutrophils and monocytes to address hyperinflammation.

Neutrophils and monocytes are the cellular mediators that drive systemic inflammation, which when spreading uncontrollably through the body can lead to organ damage, organ failure or death. The SCD technology targets the cellular drivers of inflammation to restore balance in the body and potentially reverse the damage.

SeaStar Medical said it plans to submit SCD for approval with the FDA under the Humanitarian Device Exemption to commence commercialization for the treatment of pediatric...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT